PD-L1 expression on tumor cells and tumor-infiltrating immune cells in thymic epithelial tumors detected with SP142 and SP263 antibodies
PLOS One · 2025
DOI: 10.1371/journal.pone.0327792 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Kei Chubachi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan. Hauptthemen laut MEDLINE: Thymus Neoplasms, B7-H1 Antigen, Neoplasms, Glandular and Epithelial, Lymphocytes, Tumor-Infiltrating. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Programmed death-ligand 1 (PD-L1) expression in various tumors is known to correlate with the efficacy of immune checkpoint inhibitors; however, evaluation of PD-L1 expression in thymic epithelial tumors (TETs) using multiple antibodies are limited. We retrospectivity evaluated PD-L1 expression in thymomas and thymic carcinomas using two antibodies, SP142 and SP263, and compared their expression rates in each type of TETs. Materials and methods We retrospectively included 37 cases of thymoma and 11 cases of thymic carcinoma that were histologically diagnosed between January 2000 and December 2020. PD-L1 expression was assessed using SP142 and SP263 antibodies with semi-quantitative scoring.
Results
The concordance rate for PD-L1 positivity between SP142 and SP263 was 81.2%, whereas the concordance rate for high PD-L1 expression was 83.3%. SP142 showed positive PD-L1 expression in 23 (62%) thymoma cases and eight (73%) thymic carcinoma cases. In contrast, SP263 antibody showed positive PD-L1 expression in 31 (84%) cases of thymoma and 9 (82%) cases of thymic carcinoma. In addition, type B thymomas exhibited significantly higher PD-L1 positivity than other thymoma types. The tumor-infiltrating lymphocytes were mostly CD3 and CD8 positive. No significant difference in overall survival was observed between the high and low PD-L1 expression groups in thymic carcinoma.
Conclusion
PD-L1 expression rate was high in TETs, with variations depending on the antibody used and histological subtype. SP263 showed higher PD-L1 expression compared to SP142. The type of the antibody used should be considered when evaluating PD-L1 expression in TETs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.
- Department of Anatomic Pathology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.
ORCID-Profile: Kei Chubachi
Zitieren
APA
Chubachi, K., Tanaka, H., Taima, K., Tasaka, S., & Kurose, A. (2025). PD-L1 expression on tumor cells and tumor-infiltrating immune cells in thymic epithelial tumors detected with SP142 and SP263 antibodies. PLOS One. https://doi.org/10.1371/journal.pone.0327792
Vancouver
Chubachi K, Tanaka H, Taima K, Tasaka S, Kurose A. PD-L1 expression on tumor cells and tumor-infiltrating immune cells in thymic epithelial tumors detected with SP142 and SP263 antibodies. PLOS One. 2025. doi:10.1371/journal.pone.0327792
BibTeX
@article{Chubachi2025,
author = {Chubachi, Kei and Tanaka, Hisashi and Taima, Kageaki and Tasaka, Sadatomo and Kurose, Akira},
title = {PD-L1 expression on tumor cells and tumor-infiltrating immune cells in thymic epithelial tumors detected with SP142 and SP263 antibodies},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0327792}
}
EUVIMED